Indeed, TTFA treatment sensitized AML cells to both venetoclax and the related BCL-2/BCL-xL inhibitor navitoclax (Fig. 7h,i and Extended Data Fig. 7g–k). Here, BCL2 is linked to acute myeloid leukemia.